enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
Rhea-AI Summary
enVVeno Medical (Nasdaq: NVNO) highlighted the U.S. Food and Drug Administration's first-ever IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve. The IDE positions the company to advance a potential first effective treatment option for about 3 million U.S. patients suffering from DVI.
CEO Robert Berman discussed the implications in a Virtual Investor "What This Means" segment, which is now available for viewing.
Positive
- First-ever FDA IDE for U.S. pivotal non-surgical venous valve study
- IDE approval supports potential first effective DVI treatment for ~3 million U.S. patients
Negative
- None.
News Market Reaction – NVNO
In the May 12 session, NVNO declined 5.67%, reflecting a notable negative market reaction. Argus tracked a trough of -4.1% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | +1.5% | Q1 2026 financial results and IDE-related business update with runway details. |
| Apr 29 | FDA IDE approval | Positive | -10.8% | First-ever FDA IDE approval for TAVVE pivotal study of the enVVe system. |
| Mar 27 | FY 2025 earnings | Positive | +0.8% | Full-year 2025 results and plan to initiate pivotal trial in 2026. |
| Feb 04 | Nasdaq compliance | Positive | -8.2% | Regained compliance with Nasdaq minimum $1.00 bid price requirement. |
| Jan 15 | Reverse stock split | Negative | -13.2% | 1-for-35 reverse stock split reducing outstanding shares to about 655 thousand. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent price reactions to positive milestones have been inconsistent, with FDA IDE approval and Nasdaq compliance both followed by notable selloffs, while earnings and strategic updates drew mild gains. Dilutive or structurally negative events like the reverse stock split saw aligned downside reactions.
This announcement builds on a series of FDA- and capital-structure-driven milestones. On Apr 29, 2026, NVNO received first-ever FDA IDE approval for its TAVVE pivotal study, citing an addressable U.S. population of ~3 million patients, but shares fell 10.82%. Q1 2026 and FY 2025 updates showed cash of $24.9M–$28.2M and runway into Q3 2027. Earlier, the company executed a 1-for-35 reverse split and later regained Nasdaq minimum bid compliance. Today’s video segment reiterates and contextualizes the pivotal IDE milestone rather than introducing a new clinical event.
Key Terms
fda regulatory
ide regulatory
pivotal study medical
venous valve medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve
IDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3 million U.S. patients suffering from DVI
Watch the "What This Means" video here
IRVINE, CA / ACCESS Newswire / May 12, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.
As part of the segment, Mr. Berman discussed the Company's recent news announcing the U.S. Food and Drug Administration's (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical replacement venous valve.
The Virtual Investor "What This Means" segment featuring enVVeno Medical is now available here.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire